The Food and Drug Administration (FDA) has expanded its approval of a ketamine-derived nasal spray, Spravato (esketamine), as a standalone therapy for adults with treatment-resistant depression.
Brianna is a contributing writer for InStyle covering all things beauty. She is known for discovering the coolest niche beauty brands from around the world, really good hair day tips, and best-in ...
The FDA’s latest approval of the nasal spray Spravato (esketamine) CIII marks a major shift in how major depressive disorder is managed, allowing people who have tried at least two oral ...
CVS closed nine stores in Connecticut in 2024, but they say there are no other closures planned for 2025 at this time - other than these two. They're not the only big brand store to close ...
The nasal spray Spravato, which is made from the drug esketamine, had been approved in 2019 for patients who failed to respond to at least two oral antidepressants. However, it had to be used in ...
Johnson & Johnson has announced the FDA’s approval of a first-of-its-kind, esketamine nasal spray called Spravato for the standalone treatment of major depressive disorder (MDD), PTSD ...
Jan. 21 (UPI) --The Food and Drug Administration has approved the first-ever stand-alone nasal spray to treat drug-resistant depression. Johnson & Johnson's Spravato has been approved to treat a ...
NEW YORK (PIX11) – A nose spray has been approved by the U.S. Food and Drug Administration to help treat depression, Johnson & Johnson announced on Tuesday. Spravato is a first-of-its-kind ...
Nasal sprays are available by prescription or over the counter (OTC). Most products come in a hand-operated pump bottle or squeeze bottle. Knowing how to use a nasal spray is important, as doing it ...
This article was subjected to a comprehensive fact-checking process. Our professional fact-checkers verify article information against primary sources, reputable publishers, and experts in the field.
一些您可能无法访问的结果已被隐去。
显示无法访问的结果